Ramucirumab is named as an intervention in 17 current clinical trials in our USA, China, UK, Ireland and India registers. 8 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AstraZeneca (4). The most-studied condition is Gastric Adenocarcinoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Gastric Adenocarcinoma | 4 |
| Gastroesophageal Junction Adenocarcinoma | 3 |
| Gastric Cancer | 3 |
| Gastroesophageal Junction | 2 |
| Gastric Cancer, Adenocarcinoma | 1 |
| Biliary Tract Cancer | 1 |
| Metastatic Cancer | 1 |
| Advanced Cancer | 1 |
| Metastatic Non-Small Cell Lung Cancer | 1 |
| Neoplasms | 1 |
| Child | 1 |
| Adolescent | 1 |
| Gastroesophageal Junction Cancer | 1 |
| Advanced Solid Tumors | 1 |
| NSCLC (Advanced Non-small Cell Lung Cancer) | 1 |
| Gastroesophageal Junction (GEJ) Adenocarcinoma | 1 |
| Pancreatic Adenocarcinoma | 1 |
| HER2-negative | 1 |
| Esophageal Adenocarcinoma | 1 |
| Gastroesophageal Adenocarcinoma | 1 |
| Esophageal Neoplasms | 1 |
| Esophageal Cancer | 1 |
| Solid Tumor | 1 |
| Colorectal Cancer | 1 |
| Cholangiocarcinoma | 1 |
| Bladder Cancer | 1 |
| Non-small Cell Lung Cancer | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Advanced or Metastatic Non-small Cell Lung Cancer | 1 |
| Solid Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 4 |
| Eli Lilly and Company | 3 |
| Astellas Pharma Global Development, Inc. | 2 |
| Toray Industries, Inc | 2 |
| Daiichi Sankyo | 1 |
| ALX Oncology Inc. | 1 |
| Multitude Therapeutics Inc. | 1 |
| Gilead Sciences | 1 |
| Merck Sharp & Dohme LLC | 1 |
| FBD Biologics Limited | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 15 | 8 |
| Clinical trials in China | 11 | 4 |
| Clinical trials in UK | 6 | 1 |
| Clinical trials in Ireland | 1 | 0 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
17 current trials in our USA, China, UK, Ireland and India registers name Ramucirumab as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 8 of the 17 trials are recruiting: 8 with sites in USA, 4 with sites in China and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AstraZeneca (4), Eli Lilly and Company (3), Astellas Pharma Global Development, Inc (2) and Toray Industries, Inc (2), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ramucirumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ramucirumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ramucirumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.